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ABSTRACT
EXPLORING THE INFLUENCE OF PKC PHOSPHORYLATION ON NOTCH1
ACTIVATION AND T HELPER CELL DIFFERENTIATION
September 2018
GRACE C. TROMBLEY, B.Sc., UNIVERSITY OF MASSACHUSETTS AMHERST
M.Sc., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Lisa M. Minter
The T cell-specific kinase, Protein Kinase C theta (PKC) is essential to T cell
activation and differentiation. PKC integrates T cell receptor (TCR) and CD28
signaling, and ultimately activates transcription factors necessary for full T cell
activation, proliferation, survival, and differentiation into T helper (Th) subsets.
Th1, Th2, Th17 and Treg cells compose the four major lineages of T helper cells,
differentiated from CD4 T cells, and each have different requirements for PKC.
PKC, itself, is regulated through phosphorylation of specific resides, including
tyrosine (Y)90 and threonine (T)538. Following T cell stimulation, PKC is
phosphorylated on Y90 by the kinase, LCK, and translocates to the cell membrane.
There it remains associated with LCK in a structural complex known as the
immunological synapse. Loss of PKC in T cells produces a phenotype that is similar
to loss of another important T cell protein, Notch1, suggesting these two proteins
may function in the same signaling pathway. Our lab has shown that PKC can
interact with Notch1, but how this interaction regulates Notch1 function is not
known. Due to the strong overlap between cellular functions regulated by PKC and
Notch1, understanding how these two proteins might function, cooperatively, can
provide better insight into autoimmune diseases and may be useful in developing
novel therapies
We hypothesized that phosphorylation of a specific residue of PKC (T538) is
required for Notch1 cleavage and nuclear translocation. We also hypothesize that
the phosphorylation status of PKC (T538) will influence the ability of T cells to
differentiate into specific T helper subsets. We used two means of inhibiting PKC
function to evaluate its regulation of Notch1 in differentiated T cells: 1) we blocked
the association of PKC and LCK, thereby preventing its movement to the
immunological synapse and 2) we prevented PKC phosphorylation on T538.
We found that by preventing the phosphorylation of PKC, we also decreased the
level of cleaved Notch1 in Th1, Th2, and Th17 cells. We further determined that
inhibiting PKC decreased the amount of Notch1 that translocated to the nucleus in
iv

Th1 and iTreg cells. Understanding how PKC interacts with and regulates Notch1
to influence T cell differentiation may lay the foundation for specifically modulating
T cell responses.
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CHAPTER 1
INTRODUCTION
T helper cells (Th cells) are essential in directing immune responses though
their role in activating and directing other immune cells. Upon recognition of a
foreign antigen, Th cells will stimulate antibody production by producing cytokines
that will activate other T-cell subsets, B-cells and innate immune responses. The
different CD4 T cell subsets of Th cells can be defined by their distinct cytokine
secretion patterns. They include T helper type 1 (Th1), T helper type 2 (Th2), T
helper type 17 (Th17), and regulatory T cells (Tregs). Th1 cells are essential in cellmediated immunity and in eliminating intracellular pathogens via the activation of
infected macrophages (Zhu, J., et al. 2012). Some Th1 dominant diseases include
organ-specific autoimmune disorders such as multiple sclerosis, diabetes, and
rheumatoid arthritis. Th2 cells are essential in humoral immune responses and host
defense against extracellular parasites via induction of B-cell antibody production
(Zhu, J., et al. 2012). Some conditions associated with Th2 dominance are systemic
autoimmune disorders, allergies, and asthma. Th17 cells play a role in host defense
against extracellular pathogens by mediating the recruitment of neutrophils and
macrophages to infected tissues (Zhu, J., et al. 2012). A few of the autoimmune
inflammatory diseases associated with Th17 cells are psoriasis, multiple sclerosis,
lupus, and chronic obstructive pulmonary disease. Regulatory T cells place a
negative regulation on other immune cells and therefore are capable of suppressing
an immune reaction and preventing autoimmune diseases and chronic
1

inflammatory diseases (Zhu, J., et al. 2012). Understanding the mechanisms of Treg
cells could lead to development of therapeutic strategies for diseases such as cancer,
diabetes, and immune mediated diseases. Data in the literature suggest that these
distinct subsets have different requirements for Protein Kinase C-theta (PKCθ),
these requirements being dependent upon antigen and immune response (Hayashi,
K., et al. 2008).
The T cell-specific kinase, PKCθ, is essential to T cell activation and
differentiation through the integration of TCR and CD28 signaling (Isakov, N., et al.
2002). This integration ultimately leads to the activation of transcription factors
that are necessary for full T cell survival, activation and effector function of Th
subsets. PKC, itself, is regulated through phosphorylation of specific residues,
including tyrosine (Y)90 and threonine (T)538 (Wang, X., et al. 2012). Following T
cell stimulation, PKC is phosphorylated on Y90 by the kinase, LCK, and translocates
to the membrane (Hayashi, K., et al. 2008). There it remains associated with LCK in a
structural complex known as the immunological synapse (Hayashi, K., et al. 2008).
Loss of PKC in T cells produces a phenotype that is similar to loss of another
important T cell protein, Notch1, suggesting these two proteins may function in the
same signaling pathway. Notch1, a transmembrane receptor, is known to play an
essential role of the differentiation of CD4 T cells into T helper cells (Osborne, B., et
al. 2007). Our lab has shown that PKC can interact with Notch1, but how this
interaction regulates Notch1 function is not known. Because of the strong overlap
between cellular functions regulated by PKCθ and Notch, understanding how these
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two proteins might function, cooperatively, can provide better insight into
autoimmune diseases and may be useful in developing novel therapies.
We used two means of inhibiting PKC function to evaluate its regulation of
Notch1 in differentiated T cells: 1) we blocked the association of PKC and LCK,
thereby preventing its movement to the immunological synapse and 2) we
prevented PKC phosphorylation on T538. Understanding how PKC interacts with
and regulates Notch1 to influence T cell differentiation may lay the foundation for
specifically modulating T cell responses.
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CHAPTER 2
LITERATURE REVIEW
The immune system is composed of two parts, the non-specific innate
immunity and the specific adaptive immunity. Upon infection, the innate and
adaptive immune systems become active and work together to target invading
pathogens (Figure 1). The innate immune system provides immediate defense
against infection by acting as a physical and chemical barrier. This part of the
system is also responsible for activating the adaptive immune system through
antigen presenting cells (APCs). While the innate immune system is not useful for
long-term immunity, the adaptive immune system does provide long-lasting
protection. The adaptive immune system creates an immunological memory;
therefore, it is able to ward off repeated attacks of the same specific pathogen. The
cells responsible for the adaptive immune response are the lymphocytes, a type of
white blood cell. Two different lymphocytes carry out this immune response, the B
cells and T cells. The B cells are produced in the bone marrow and either form into
memory cells or plasma cells which are responsible for secreting antibodies.
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Figure 1: (VMC 2012) Overview of the adaptive and innate immune systems.
T cells, a type of white blood cell, play a central role in the adaptive immune
system. Complete activation of T cells requires signaling events through the antigenspecific receptor as well as one through the receptor for a co-stimulatory molecule.
Without the co-stimulatory molecule, the T cell is incapable of producing its own
growth hormone, interleukin 2 (IL-2), upon stimulation (Schwartz, R. 1990). T cells
differentiate in response to activation, resulting in the T cells being capable of
producing other cytokines that will serve as effector molecules through the
activation of other cells. This cycle causes the T cells to proliferate, which is
essential for their role in host defense. T cells can become effector cells that will
develop either as T helper (Th) cells or as cytotoxic T (Tc) cells. T cells that mature
in the thymus will migrate to peripheral lymphoid organs such as the spleen and
lymph node (Schwartz, R. 1990). It is here that naïve T cells will encounter antigens
through antigen presenting cells (APCs).
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Antigens are taken up by APCs, are fragmented into peptides, and complexed
with major histocompatibility complex (MHC) on the APC surface to present to T cell
antigen receptors (Kwon, M., et al. 2010). Upon engagement of the MHC-peptide
with the TCR, the TCR initiates signaling pathways that lead to activation of T cells.
The T cell antigen receptor (TCR) is a protein complex responsible for signal
transduction following recognition. These antigen receptors are composed of two
disulfide-linked subunits (α and β) which come into contact with the peptide and
the MHC (Schwartz, R. 1990). After attachment to these chains, the CD4 or CD8
molecule is brought into the receptor complex. MHC class I molecules are
recognized by lymphocytes expressing the CD8 surface molecule while the MHC
class II molecule is recognized by lymphocytes expressing the CD4 surface molecule
(Figure 2). When T cells become activated upon recognition of a foreign antigen, the
naïve cells will proliferate in response to their own production of the proliferative
cytokine, IL-2.
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Figure 2: (Teichgraber, V. 2004) CD4 and CD8 T cell signaling. CD4 and CD8 T cell
surface molecules bind to their respective class I or class II major histocompatibility
complex (MHC) ligands on an antigen presenting cell (APC).
CD4 T cells are essential to the adaptive immune response through their role
in helping B cells to produce antibody and undergo maturation, as well as activating
other immune cells such as CD8 T cells. Once CD4 T cells are activated, they are
primed to differentiate into T helper cells that are responsible for mediating
pathogen-specific immune responses. T helper cells, or Th cells, differentiated from
naïve CD4 T cells, make up four major lineages: Th1, Th2, Th17 and T regulatory
(Treg) cells. Their differentiation depends on function, cytokine secretion, and
expression of transcription factors (Figure 3). Th1 cells produce IFNγ, making these
cells essential in macrophage activation as well as in elimination of intracellular
pathogens. The cytokines that direct the Th1 differentiation process are IL-12 and
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IFN (Zhu, J., et al. 2012). Th2 cells produce IL-4, IL-5, IL-10 and IL-13, making these
cells essential in Immunoglobulin E production and in the elimination of
extracellular parasites (Zhu, J., et al. 2012). The cytokines that promote a Th2
phenotype are IL-4, TSLP, IL-17 and IL-2 (Zhu, J., et al. 2012). Th17 cells produce
many cytokines and are essential in immune responses to extracellular bacteria and
fungi (Zhu, J., et al. 2012). Cytokines involved in the Th17 differentiation process are
TGF, IL-6, IL-21, and IL-23 (Zhu, J., et al. 2012). Regulatory T cells consist of
naturally occurring Tregs (nTregs) and inducible regulatory Tregs (iTregs). The
nTregs develop in the thymus while the iTregs are caused by exposure of naïve
peripheral CD4 T cells with a TCR stimulant along with TGF and IL-2 (Zhu, J., et al.
2012). Both types of Tregs are involved in self-tolerance as well as immune
modulation. The cytokines that promote the Treg differentiation process are TGF
and IL-2 (Zhu, J., et al. 2012).
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Figure 3: (Bailey, S., et al. 2014) Differentiation of Naïve T cells into T helper
subsets. Based upon the cytokines surrounding their environment, naïve T cells will
differentiate into a specific T cell phenotype that is characterized by distinctive
cytokine expression.
Protein Kinase C theta (PKCθ) is a serine/threonine kinase and a member of
the novel protein kinase C (PKC) subfamily. PKC kinases are regulated by calcium,
diacylglycerol, and phorbol esters and are separated into three major groups by
their activating factors (Xu, Z., et al. 2004). These kinases have a C-terminal catalytic
kinase domain and an N-terminal regulatory co-factor-binding domain (Xu, Z., et al.
2004). Expression of this protein is limited to certain tissues and cell types, which
includes T cells. We know that PKCθ is required for the survival and activation of
mature T cells due to its major role in coupling the activated T cell receptor and the
CD28 costimulatory receptor to their signaling pathways (Isakov, N. 2012). Upon
antigen stimulation, PKCθ translocates to membrane lipid rafts, and from there
9

localizes to the immunological synapse (IS) (Cartwright, N., et al. 2011). PKCθ-/- mice
were found to have impaired T cell activation and proliferation due to defects of
activator protein-1 (AP-1), nuclear factor-B (NF-B), and IL-2 induction
(Cartwright, N., et al. 2011). This impairment was found to affect the CD4 T cells
more severely than the CD8 T cells (Cartwright, N., et al. 2011). PKCθ-/- T cells have
also shown defects in cytokine production and differentiation.
During TCR stimulation, phosphorylation of PKCθ occurs at multiple serine,
threonine, and tyrosine residues. PKCθ consists of a N-terminal regulatory region
and a C-terminal catalytic region. On the outside of the C1 domains are two variable
regions, V1 and V3 (Wang, X., et al. 2012). The site of phosphorylation responsible
for bringing PKCθ to the IS resides in the V3 domain of PKCθ, where it is involved in
the indirect association of PKCθ and CD28 (Isakov, N. 2007). TCR and CD28 costimulation induces production of diacylglycerol; diacylglycerol binds to the C1
domains of PKCθ, which in turn exposes the activation loop of PKCθ (Wang, X., et al.
2012). Once this occurs, the germinal center kinase-like kinase (GLK) is able to
phosphorylate Threonine 538 and subsequently induce catalytic activation (Wang,
X., et al. 2012). The C2-like domain region of PKCθ contains a phosphorylated Y90
residue which is thought to interact with a SH-2 domain containing region (Wang, X.,
et al. 2012). Additionally, the C2-like domain may interact with a receptor for
activated C kinase (RACK), a possible regulator of PKCθ translocation to the
membrane (Wang, X., et al. 2012).
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Figure 4: (Wang, X., et al. 2012) TCR Signaling via PKCθ. Activation of the TCR
starts a signaling cascade which leads to the phosphorylation of PKCθ and induces
its translocation to the membrane. This translocation facilitates the activation of
transcription factors essential for T cell activation.
Localization of PKCθ to the immunological synapse (IS) is thought to access
downstream targets as well as contribute to CD28-mediated co-stimulation
(Cartwright, N., et al. 2011). When PKCθ is active and retained at the IS, it will
initiate a signaling cascade that leads to the activation of transcription factors
including nuclear factor-kB (NF-kB), AP-1, and NF-AT, all of which are essential in T
cell proliferation and differentiation (Figure 4). This is due to their corresponding
binding sites on the IL-2 gene promoter and are, therefore, essential for an optimal
IL-2 response (Isakov, N. 2012). Alternatively, it was found in Tregs that PKCθ will
translocate to the opposite cell pole, away from the IS. Other data has shown that
this localization may control IS stability (Cartwright, N., et al. 2011). The IS, also
11

known as the supramolecular activation cluster (SMAC), is the region containing the
site of contact between antigen (Ag)-specific T cells and Ag-presenting cells (APCs)
(Hayashi, K., et al. 2007). The IS serves to deliver activation signals that are required
for productive T cell activation. The central SMAC (cSMAC) contains a high content
of TCR, PKCθ, co-stimulatory receptors CD28, CD2, CD4, and CD8, and kinases LCK
and FYN (Hayashi, K., et al. 2007). The cSMAC contains two separate compartments
that are responsible for different functions, the first containing TCR-associated
signaling complexes that are internalized and degraded while the second
compartment, containing large amounts of PKCθ and CD28, is the site of colocalization between these proteins (Isakov, N. 2012).
CD28 is a homodimeric glycoprotein that is expressed by mature T cells as a
surface molecule and acts as a co-stimulatory signal receptor for T cell activation
(Nunes, J., et al. 1996). CD28 co-stimulation has been found to enhance translocation
of PKCθ to the lipid rafts and the IS (Hayashi, K., et al. 2007). In combination with
this signaling, TCR signaling leads to T cell proliferation and differentiation through
activation of transcription factors NF-κB and AP-1 (Hayashi, K., et al. 2007). There
are binding sites for these transcription factors on the IL2 gene promoter, therefore
signaling is followed by the activation of the IL2 gene promoter (Isakov, N. 2012).
Studies have shown that co-stimulation between the TCR and CD28 induces binding
of PKCθ to the cytoplasmic tail of CD28 (Isakov, N. 2012). Additionally, it was
discovered that functional LCK, a Src protein-tyrosine kinase, is required in order
for PKCθ to translocate to the IS (Hayashi, K., et al. 2007).

12

Six different phosphorylation sites that contribute to the regulation of PKCθ
kinase activity and membrane translocation were discovered on PKCθ: S676, S685,
S695, T219, T538, and Y90 (Figure 5; Wang, X., et al. 2012). According to previous
data, preventing the phosphorylation of T538 with a T538A mutant eliminated
PKCθ activity, suggesting that T538 is a critical phosphorylation site for PKCθ
function (Wang, X., et al. 2012). Certain peptide sequences within the PKCθ Cterminal fragments are required for IS retention while multiple phosphorylation
sites in the PKCθ Kinase Domain contribute to protein stability and kinase activity.
These residues include Thr-538 in the activation loop, Ser-676 in the turn motif, and
Ser-695 in the hydrophobic domain (Cartwright, N., et al. 2011). In previous studies,
a T538A mutation was found to cause poor IS retention, indicating that
phosphorylation of Thr-538 is responsible for the IS retention of PKCθ (Cartwright,
N., et al. 2011). This demonstrates a strong correlation between PKCθ kinase
activity and IS retention.
Additionally, it was discovered that specific T cell subpopulations have
different requirements for PKCθ, which is dependent upon the type of antigen and
immune response (Isakov, N. 2007). PKCθ is required for developing Th2dependent immunity in vivo and is critical in Th17 responses as well (Hayashi, K., et
al. 2007). As previously mentioned, when Tregs are activated, PKCθ is pulled in the
opposite direction of the IS. When inhibiting PKCθ, there is an increase in the
suppressive activity of Tregs (Isakov, N. 2007). PKCθ is known to mediate a negative
feedback on Tregs and their functions, which subsequently will downregulate
certain functions of T effector cells (Isakov, N. 2007). Under normal conditions,
13

suppressed T cells will show a decrease in CD69 up-regulation, decrease of IL-2
secretion, and an impaired proliferative response (Isakov, N. 2007). In PKCθdeficient cells, it has been reported that these cells are not able to up-regulate CD69
and without translocation of PKCθ to the IS, TCR-dependent proliferation will not
occur (Isakov, N. 2007). Additionally, T cells that were pulsed with suboptimal
concentrations of antigen were not able to recruit PKCθ (Isakov, N. 2007).

Figure 5: (Isakov, N., 2012) Structure of PKCθ.
An essential part of the adaptive immune response is a functional CD8 T cell
response. When encountering an antigen, the naïve CD8 T cells differentiate into
CD8 effectors, then produce cytokines such as IFNγ as well as the effector molecules
perforin and granzyme B (Cho, O., et al. 2009). These effector cytotoxic T cells are
essential in the immune defense against intracellular bacteria and viruses. They
produce this defense by perforin-mediated release of granzyme B, which causes
apoptosis (Cho, O., et al. 2009). Another system of defense includes the expression
of the FAS ligand, which works by attaching to FAS on a target cell, inducing
apoptosis (Cho, O., et al. 2009).
14

The Notch signaling pathway is responsible for regulating interactions
between neighboring cells. This communication either promotes or suppresses
differentiation, proliferation and cell death (Kopan, R., et al. 2009). Notch proteins
are single-pass transmembrane receptors that are cleaved multiple times before
coming to the cell surface as a heterodimer. The final cleavage is completed by
gamma-secretase (GSI). From this cleavage, the Notch intracellular domain (NCID) is
generated (Osborne, B. et al. 2007). This intracellular signaling peptide translocates
to the nucleus, where it associates with a DNA-bound Suppressor of Hairless (Su(H))
and the nuclear effector Mastermind (MAM), leading to the activation of
transcriptional activity (Guruharsha, K., et al. 2012).
Notch proteins play a role in controlling cell fate decisions as well as affecting
peripheral T cells (Figure 6). Notch receptors have been shown to be responsible
for regulating transcription factors NF-B, IFN, IL-4, and enhancer CSN2, proteins
that are essential to peripheral T cell activation and differentiation (Osborne, B. et
al. 2007). There are four mammalian Notch receptors, Notch1, Notch2, Notch3, and
Notch4 along with five canonical Notch ligands Jagged1, Jagged2, DLL1 (Delta-Like
1), DLL2, DLL3, and DLL4 (Osborne, B. et al. 2007). Reports have shown that
without Notch, lymphoid progenitors entering the thymus were not able to initiate a
T cell development and subsequently developed into B-cells (Osborne, B. et al.
2007). One study demonstrated that pharmacological inhibitors that were used to
block the upregulation of Notch expression in peripheral CD4 T cells also inhibited T
cell proliferation along with IFN- production following stimulation via the TCR
(Osborne, B. et al. 2007). Additionally, it was discovered that a positive feedback
15

loop involving Notch signaling is responsible for regulating IL-2 production and the
expression of CD25, an IL-2 receptor, via T cells. (Osborne, B. et al. 2007). Another
study reported that Notch proteins co-localize with CD4 in human CD4 T cells. This
localization would place the proteins at the IS, where it would be capable of
modulating early signaling events in activated T cells (Osborne, B. et al. 2007).
Signaling through the TCR induces activation of Notch1 in both CD4 and CD8
T cells (Cho, O., et al. 2009). Activation of Notch leads to the activation of NF-B
which subsequently leads to the expression of genes needed for a Th1
differentiation, such as T-bet and IFN (Osborne, B. et al. 2007). This suggests that
Notch proteins have a role in the differentiation of CD4 T cells into Th1 cells. When
CD4 T cells are differentiated to Th2 cells, Notch proteins are also required for the
production of IL-4 by NKT cells and memory CD4 T cells (Osborne, B. et al. 2007).
Notch proteins may also have a role in Treg differentiation by ligation via Notch
receptors on T cells with Jagged 1 or DLL1 on APCs, which can lead to the
generation of CD4+ CD25+ Tregs as well as CD8 Tregs (Osborne, B. et al. 2007).
Another study found that in Notch1, in vivo, acts in the same functional
pathway as PKCθ and that Notch1 associates with PKCθ and Carma1 in the cytosol
(Shin, H., et al. 2014). PKCθ is known to have distinct nuclear and cytoplasmic
functions. Following T cell activation, studies have reported a rise in the activity of
cytoplasmic PKCθ while no change was seen in the nuclear fraction (Isakov, N.
2007). Notch-receptor upregulation is also seen to occur with stimulation of CD4 T
cells with CD3- and CD28-antibodies (Osborne, B., et al. 2007).
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Notch regulates cytotoxic T cells through regulation of eomesodermin
(EOMES), perforin, and granzyme B (Cho, O., et al. 2009). EOMES expression,
combined with the expression of the T-bet transcription factor, is partly responsible
for the differentiation of naïve T cells into effector cytotoxic T cells. T-bet plays a
role in the development of CD8 T cells, demonstrating another role on Notch in the
regulation in cytotoxic T cells (Cho, O., et al. 2009).
In multiple human disorders including human genetic disorders and cancer,
the impairment of the Notch signaling pathway has been reported as the underlying
cause. In studies with impaired Notch1 signaling, a reduced CD25 expression, a
decrease in IL-2 production, and a decrease in proliferation have all been observed
(Shin, H., et al. 2014). Additionally, it was reported when upregulation of Notch
expression is inhibited, T-cell proliferation and IFNγ production is also inhibited
(Osborne, B., et al. 2007). Notch signaling has an essential role in cell fate decisions
throughout various stages of T-cell development.

17

Figure 6: (Nakano, T., et al. 2016) Notch signaling pathway. Upon ligand/receptor
interaction, cleavages at S2 and S3 allow the Notch intracellular domain (NICD) to
translocate into the nucleus where it associates with a transcription factor and
activates transcription.
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CHAPTER 3
METHODS
CD4 T cell isolation.
Following the humane euthanasia of a mouse, the spleen was harvested and
passed through a filter to collect the splenocytes. Red blood cells were lysed with
ACK buffer and white blood cells were counted with a hemocytometer. CD4 T cells
were isolated using anti-mouse CD4 magnetic particles (BD Biosciences) and
separated using the BD IMAG Cell Separation Magnet.
Flow cytometric analyses of protein expression.
The CD4 T cells were pretreated with either DMSO, the vehicle control, 3 μM
Rottlerin, or 5 μM Complegen inhibitor, CGX0486, for 30 minutes at 37C. Following
treatment, the cells were polarized into specific T helper cell subsets, each requiring
their own respective polarizing agents:

Cells were stimulated by plating onto anti-CD3-plus anti-CD28-coated wells
and incubated at 37C. The cells were harvested at 24-, 48- and 72-hour timepoints.
The supernatant was collected and stored for cytokine analysis by ELISA. The cells
19

were harvested and stained with Zombie Fixable Viability Dye (BioLegend) for 15
minutes at 2-8C, then pelleted by centrifugation for 5 minutes. Cells were
resuspended in 0.2% bovine serum albumin (BSA) in PBS and incubated for 30
minutes at 2-8C. After this incubation, the cells were stained with antibodies for
Notch1IC, pPKCθ, and their respective master transcription factor, T-Bet (Th1),
GATA-3 (Th2), RORγt (Th17), or FOXP3 (iTreg). Flow Cytometry was used to
analyze the expression of the proteins. Lastly, cytosolic vs nuclear PKCθ as well as
cytosolic vs nuclear Notch1IC levels were assessed by imaging flow cytometry. One
thousand cells were visualized and fluorescent intensities were quantified using an
AMNIS ImageStream X Mark II Imaging Flow Cytometer at 60X magnification. To
determine nuclear localization of desired proteins, the nuclear localization wizard
was applied in the IDEAS software upon masking the nuclear area (Intensity mask:
Ch05-DRAQ5 staining). We also determined the percent of cells showing nuclear or
non-nuclear expression of PKC and Notch1 by applying the AMNIS nuclear masking
wizard.
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CHAPTER 4
RESULTS
Mouse CD4 T cells were isolated and differentiated in vitro into Th1, Th2,
Th17, or Treg subsets. The cells were treated with an inhibitor that prevented PKC
from interacting with LKC (Complegen) or with a PKC-specific inhibitor, Rottlerin,
that prevents PKC phosphorylation on the Thr538 residue. The cells were analyzed
24, 48, and 72 hours after differentiating them in culture, and we measured percent
positive and median fluorescent intensity of pPKC, NOTCH1 and each of the
signature transcription factors, in each subset.
We first wanted to confirm that the CGX inhibitor reduced
PKC phosphorylation, then we asked what effect this had on different T cell
subsets. In Th1 cells, we observed a decrease in the percent positive cells for
phosphorylated PKCθ (T538) when the cells were treated with 5μM Complegen
(CGX) inhibitor (Figure 7), while PKC phosphorylation was not affected following
treatment with 3μM Rottlerin. In the CGX-treated cells we also observed a decrease
in the median fluorescence intensity of phosphorylated PKCθ (T538) 48 and 72
hours after stimulation (Figure 8). In Th1 cells, Rottlerin treatment decreased the
percent positive NOTCH1 cells, as well as the median fluorescent intensity of
NOTCH1 at all time points (Figure 9). CGX treatment had no effect on NOTCH1
positive cells or the median fluorescent intensity (Figure 10). T-Bet, the master
transcription factor of Th1 cells, was not affected by CGX treatment. When T cells
were treated with Rottlerin, there was a decrease in the percent of T-Bet positive
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cells (Figure 11) and median fluorescence intensity at all time points. In Th1 cells,
we observed a small decrease in nuclear NOTCH1 when the cells were treated with
Rottlerin. However, when treated with the CGX inhibitors, we did not observe a
change in NOTCH1 nuclear localization (Figure 12). We also observed a large
decrease in the median fluorescent intensity of NOTCH1, both nuclear and nonnuclear, when the Th1 cells were treated with Rottlerin (Figure 13). In the Th1
cells, we observed a decrease in nuclear PKC in CGX-treated cells, and a small
decrease in the Rottlerin-treated cells (Figure 14). The median fluorescence
intensity of non-nuclear PKC in the Rottlerin-treated cells was slightly decreased,
while the CGX treated cells showed an increase in nuclear PKC and a decrease in
non-nuclear PKC (Figure 15). In Th1 cells, we observed colocalization of PKC and
NOTCH1 was not much affected by the inhibitor treatments (Figure 16). The
signature cytokine of Th1 cells, IFNγ, was decreased after treatment with either
inhibitor at the 48- and 72-hour time points (Figure 17). Rottlerin treatment had a
greater effect on the decrease in production of IFNγ than the CGX inhibitor. We can
conclude from these data that both CGX and Rottlerin affect PKC signaling in Th1
cells, but they appear to act by different mechanisms, since we did not see identical
results with the two inhibitors. Interestingly, even though we didn’t see strong
effects on PKC phosphorylation in Rottlerin-treated Th1 cells, there was a
significant decrease in T-bet expression and IFN expression, suggesting Rottlerin
may have other actions beyond inhibiting PKC phosphorylation.
We next compared the effects of CGX and Rottlerin on Th2 cell
differentiation. In Th2 cells, treatment with Rottlerin produced an increase at 24
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hours followed by a decrease at the 48- and 72-hour time points in percent of cells
positive for phosphorylated PKCθ (T538). Treatment with the CGX inhibitor also
produced a decrease in percent of cells positive for phosphorylated PKCθ (T538) 48
and 72 hours after stimulation; however, this decrease was much greater than in
cells treated with Rottlerin (Figure 18). The same trend was seen in the median
fluorescence intensity of pPKC, with an initial increase followed by a decrease in
Rottlerin-treated Th2 cells. Again, a greater decrease was seen in the CGX-treated
Th2 cells, at the 48- and 72-hour time points (Figure 19). In Th2 cells, the percent of
NOTCH1 positive cells (Figure 20), as well as the median fluorescence intensity of
NOTCH1 (Figure 21), showed a decrease at all time points in the Rottlerin-treated
cells. When we measured the percent of positive cells expressing GATA-3, the
master transcription factor of Th2 cells, we observed a decrease at all time points in
Rottlerin-treated cells. CGX-treated cells showed a slight decrease in the percent of
positive cells expressing GATA-3 by 24 hours after stimulation, but no effect on the
percent of GATA-3 positive cells at the 48- and 72-hour time points (Figure 22). The
same trend observed in the percent of positive cells was also seen in the GATA-3
median fluorescent intensity of both the Rottlerin-treated and CGX-treated cells
(Figure 23). For IL-4, the signature cytokine of Th2 cells, Rottlerin treatment had
little effect on IL-4 levels. The CGX inhibitor; however, decreased IL-4 production at
24 hours but showed an increase by 72 hours (Figure 24). These data suggest that
Th1 and Th2 cells differ in how sensitive they are to the effects of CGX and Rottlerin.
Like Th1 cells, CGX treatment showed a greater reduction on PKC phosphorylation,
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but unlike the very strong inhibiting effects Rottlerin had on T-bet, it had much less
effect on GATA-3 expression.
We also were interested in understanding the effects of CGX and Rottlerin on
Th17 cells. Th17 cells showed a decrease in the percent of phosphorylated
PKCθ (T538) positive cells in cells treated with Rottlerin, and a greater decrease in
percent of phosphorylated PKCθ (T538) positive cells was observed with CGX
treatment, 24 and 48 hours after stimulation. By 72 hours, neither inhibitor showed
any effect on the percent of phosphorylated PKCθ positive cells (Figure 25). When
we measured the median fluorescent intensity of phosphorylated PKCθ (T538), we
observed decreased expression of phosphorylated PKCθ throughout all time points
for both inhibitors (Figure 26). In CGX-treated cells, we observed decreased percent
NOTCH1 positive cells and median fluorescent intensity 24 and 48 hours after
stimulation. In Rottlerin-treated Th17 cells, the percent of NOTCH1 positive cells
was reduced only at 24 hours, while the CGX inhibitor had no effect on the percent
of NOTCH1 positive Th17 cells at any time point (Figure 27). The median
fluorescence intensity for NOTCH1 in CGX-treated cells decreased by 48 hours after
stimulation. Rottlerin-treated cells showed decreased median fluorescent intensity
of NOTCH1 at the 48- and 72-hour time points (Figure 28). When we examined the
percent positive cells expressing RORγt, the master transcription factor of Th17
cells, neither Rottlerin nor the CGX inhibitor had any effect (Figure 29). However,
when we measured the median fluorescence intensity of RORt, we observed that
both inhibitors produced increased RORt expression 48 hours after stimulation,
with no change at the 24- and 72-hour time points (Figure 30). In the treated TH17
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cells, we did not observe significant changes in the percent of cells expressing
nuclear NOTCH1 (Figure 31); however, we did observe significantly decreased
median fluorescence intensity of nuclear NOTCH1, when Th17 cells were treated
either with Rottlerin or CGX (Figure 32). In Th17 cells, we did not observe
significant effects on percent of cells expressing nuclear PKC (Figure 33) following
treatment with either inhibitor but we did observe a slight decrease in the median
fluorescent intensity of the inhibitor-treated cells, with the CGX inhibitor having a
greater impact (Figure 34). In Th17 cells, unlike in Th1 or in Th2 cells, Rottlerin and
CGX appeared to have very similar effects on PKC phosphorylation, and Notch1 and
RORt expression.
Finally, we investigated the effects of CGX and Rottlerin on regulatory T cells.
In Tregs, treatment with the CGX inhibitor caused a decrease in the percent of cells
positive for phosphorylated PKCθ (T538) 72 hours after stimulation. This inhibitor
had no effect at the 24 -and 48-hour time points of pPKCθ (T538). Treatment with
Rottlerin showed the opposite, with a decrease in percent of phosphorylated PKCθ
(T538) positive cells at the 24- and 48-hour time points. Rottlerin showed no effect
on percent of pPKCθ (T538) positive cells at 72 hours (Figure 35). The same trend,
for both inhibitors, was observed when we measured the median fluorescence
intensity of phosphorylated PKCθ (T538) (Figure 36). For Treg cells, neither
inhibitor had an effect on the percent of NOTCH1 positive cells, (Figure 37), but
both inhibitors resulted in decreased median fluorescence intensity for NOTCH1 at
24 hours (Figure 38). There was no change in percent of FOXP3 positive cells after
treatment with either inhibitor (Figure 39). However, Rottlerin treatment
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decreased the median fluorescence intensity of FOXP3 24 hours after stimulation
and increased it by 72 hours. After treatment with CGX, the median fluorescent
intensity of FOXP3 decreased at the 24- and 48-hour time points. By the 72-hour
time point, we observed a small increase in the FOXP3 levels (Figure 40). We
observed the same trend in the percent of nuclear NOTCH1 positive cells, that we
did with the percent of nuclear PKC positive Treg cells. In Treg cells, we observed
decreased percent of nuclear-expressing NOTCH1 cells following Rottlerin
treatment, but we did not observe any change in cells treated with CGX (Figure 41).
In the Rottlerin-treated cells, we also observed a large decrease in the median
fluorescent intensity of nuclear and non-nuclear NOTCH1. The CGX-treated cells had
a smaller decrease in NOTCH1 nuclear median fluorescent intensity while there was
no change in non-nuclear NOTCH1 expression (Figure 42). We observed a slight
decrease in the percent of nuclear PKC-expressing cells following Rottlerin
treatment (Figure 43), together with a significant decrease in the median
fluorescent intensity both of nuclear and non-nuclear PKC (Figure 44). In CGXtreated cells, we observed no change in the percent of nuclear PKC positive cells,
but we did observe decreased median fluorescent intensity of nuclear PKC. We
observed that, In Treg cells, while many of the cells stain double-positive for
NOTCH1 and PKC, only a small percentage of these cells show nuclear
colocalization of these two proteins. When Tregs were treated with Rottlerin, we
observed decreased percentages of double-positive cells, but no significant changes
in the nuclear colocalization of NOTCH1 and PKC. In CGX-treated Treg cells, we
observed slightly decreased nuclear colocalization of these two proteins (Figure
26

45). The most striking difference we observed between Tregs, and Th1 cells was the
effect of CGX on PKC phosphorylation. In Th1 cells, CGX-treatment significantly
reduced PKC phosphorylation, while in Tregs, CGX-treatment did not seem to affect
PKC phosphorylation. However, both Rottlerin and CGX reduced nuclear colocalization of Notch1 and PKCq in Tregs. Whether or not this observation correlates
with differences in Treg suppression will need to be investigated further.
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CHAPTER 5
DISCUSSION
To further understand the influence of PKC on Notch1 cleavage and nuclear
translocation, we inhibited pPKC function to evaluate its regulation of Notch1 in
differentiated T cells. Additionally, to explore the influence of the phosphorylation
of PKCθ on the ability of T cells to differentiate into specific T helper subsets, we
inhibited pPKC function to determine its role in T cell differentiation.
Our data suggests that the Complegen inhibitor, CGX, works to prevent the
phosphorylation of PKCθ (T538) in Th1, Th2 and Th17 cells, particularly by 72
hours following stimulation. Therefore, we can conclude that by preventing the LCK
association with PKCθ, we are preventing PKCθ localization to the Immunological
Synapse and ultimately inhibiting the phosphorylation of PKCθ (T538).
From our data, we can also conclude that treating Th cells with the PKC
inhibitor, Rottlerin, we are causing decreased Notch1 expression in Th1, Th2, and Th17
cells. This suggests that the PKC signaling is indeed essential to Notch1 cleavage and
translocation. Additionally, in cells treated with Rottlerin we saw decreased levels of
nuclear Notch1 in Th1, Th17 and Treg cells. This suggests that treatment with Rottlerin
prevents nuclear translocation of Notch1 in Th1, Th17, and Treg cells.
Finally, in Rottlerin-treated cells, we see decreased levels of T-bet in Th1 cells
and GATA-3 in Th2 cells, the signature transcription factors in both cell subsets. These
data suggest that Rottlerin reduces the ability of naïve T cells to polarize into Th1 or Th2
cells, while in their optimal polarizing conditions.
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Altogether, we have demonstrated that the phosphorylation of PKC at T538 is
essential to 1) Notch1 cleavage and nuclear translocation and 2) differentiation into
specific T cell subsets. Further investigation into the PKC-Notch1 relationship will
advance our understanding of how PKCθ and Notch1 function in the same signaling
pathway and may provide insight into autoimmune diseases and lay the foundation for
novel therapies.
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APPENDIX
FIGURES

Figure 7: Percent of pPKCθ (T538) positive Th1 cells. Complegen inhibitor
treatment decreased the percent of pPKCθ (T538) positive Th1 cells at 48 and 72
hours after stimulation. Rottlerin treatment had little to no effect.

Figure 8: MFI of pPKCθ (T538) in Th1 cells. Complegen inhibitor treatment
decreased the median fluorescent intensity of pPKCθ (T538) in Th1 cells, especially
48 and 72 hours after stimulation. Rottlerin treatment had no effect.

30

Figure 9: Percent of Notch1 positive Th1 cells. Rottlerin treatment decreased the
percent of Notch1 positive Th1 cells at all time points. The Complegen inhibitor
treatment showed no effect.

Figure 10: MFI of Notch1 in Th1 cells. Rottlerin treatment decreased the median
fluorescent intensity of Notch1 at all time points in Th1 cells. Complegen inhibitor
treatment showed no effects.
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Figure 11: Percent of T-Bet positive cells. Percent of T-Bet positive Th1 cells
decreased slightly after Rottlerin treatment at 48 and 72 hours after stimulation.
Complegen inhibitor treatment had no effect on percent of T-Bet positive cells.

Figure 12: MFI of T-Bet positive cells. Median fluorescent intensity of T-Bet in Th1
cells is decreased at all time points following Rottlerin treatment, while Complegen
inhibitor treatment had no effect.
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Figure 13: Percent of Nuclear Notch1 positive Th1 cells. Nuclear Notch1 in T
helper 1 cells is decreased by the Rottlerin while the Complegen inhibitor had no
effect.

Figure 14: MFI of Nuclear and Non-nuclear Notch1 in Th1 cells. The median
fluorescent intensity in T helper 1 cells is decreased in both nulcear and non-nuclear
Notch1 by Rottlerin. Nuclear Notch1 is decreased by CGX treatment.
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pPKCθ
Figure 15: Percent of Nuclear pPKCθ (T538) positive Th1 cells. In T helper 1
cells, a small decrease is seen in nuclear pPKC in Rottlerin treated cells with a
larger decrease in nuclear pPKC in CGX treated cells.

Figure 16: MFI of Nuclear and Non-nuclear pPKCθ in Th1 cells. The median
fluorescent intensity of nuclear pPKC in T helper 1 cells is increased by CGX
treatment.
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Figure 17: Percent of Nuclear Notch1 and pPKCθ-Colocalizing Th1 cells. No
change in colocalization of pPKC and NOTCH1 in T helper 1 cells from either
inhibitor.

Figure 18: IFNγ produced by Th1 cells. Rottlerin-treated cells showed decreased
IFNγ production by Th1 cells 48 and 72 hours after stimulation. Complegen
inhibitor-treatment resulted in slightly decreased IFN production 72 hours after
stimulation.
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Figure 19: Percent of pPKCθ (T538) positive Th2 cells. Both Complegen
inhibitor treatment and Rottlerin treatment decreased the percent of pPKCθ (T538)
positive Th2 cells, 48 and 72 hours after stimulation. Complegen inhibitor
treatment resulted in a larger decrease in percent of pPKCθ (T538) positive cells 72
hours after stimulation.
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Figure 20: MFI of pPKCθ (T538) in Th2 cells. Complegen inhibitor treatment
decreased the median fluorescent intensity of pPKCθ (T538) in Th2 cells, 48 and 72
hours after stimulation. Rottlerin treatment resulted in increased pPKCθ (T538)
expression 24 and 48 hours after stimulation.
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Figure 21: Percent of NOTCH1 positive Th2 cells. Rottlerin treatment decreased
the percent of Notch1 positive Th2 cells at all time points. Complegen inhibitor
treatment resulted in decreasd percent of Notch1 positive cells 24 and 48 after
stimulation, but showed no effect by 72 hours.

Figure 22: MFI of Notch1 in Th2 cells. Rottlerin treatment decreased the median
fluorescent intensity of Notch1 at all time points in Th2 cells. Complegen inhibitor
treatment resulted in a slight decrease in the median fluorescent intensity of Notch1
24 and 48 hours after stimluation.
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Figure 23: Percent of GATA-3 positive cells. Rottlerin treatment reduced the
percent of GATA-3 positive Th2 cells at all time points. Complegen inhibitor
treatment slightly reduced the percent of T-Bet positive cells 24 hours after
stimulation, but not at later time points.
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Figure 24: MFI of GATA-3 positive cells. Rotterin treatment reduced the median
fluorescent intensity of GATA-3 in Th2 cells at all time points. Complegen inhibitor
treatment resulted in a small decrease in the median fluorescent intensity of GATA3 at 24 and 48 hours after stimulaton.
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Figure 25: IL-4 levels in Th2 cells. Rottlerin treatment had little effect on IL-4
production by Th2 cells. Complegen inhibitor treatment decreased IL-4 production
24 hours after stimulation, but increased IL-4 production by 72 hours.
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Figure 26: Percent of pPKCθ (T538) positive Th17 cells. Rottlerin treatment
and Complegen inhibitor treatment, both, decreased the percent of pPKCθ (T538)
positive Th17 cells at 24 and 48 hours after stimulation, with slightly greater
reduction observed after Complegen inhibitor treatment. By 72 hours after
stimulation, neither inhibitor showed a significant effect on percent of pPKCθ
(T538) positive Th17 cells.
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Figure 27: MFI of pPKCθ (T538) in Th17 cells. Rottlerin tretment and Complegen
inhibitor treatment, both, decreased in the median fluorescent intensity of pPKCθ
(T538) in Th17 cells, at all time points.

Figure 28: Percent of NOTCH1 positive Th17 cells. Rottlerin treatment reduced
the percent of NOTCH1 positive Th17 cells, 24 hours after stimulation, but had no
effect 48 or 72 hours after stimulation. Complegen inhibitor treatment followed the
same trend, decreasing the percent NOTCH1 positive Th17 cells by 24 hours, but
showing no effect 48 and 72 hours after stimulation.
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Figure 29: MFI of NOTCH1 in Th17 cells. Rottlerin treatment decreased the
median fluorescent intensity of NOTCH1 48 and 72 hours after stimulation.
Complegen inhibitor treatment decreased NOTCH1 median fluorescent intensity 48
hours after stimulation, but no differences were observed at the 24- and 72-hour
timepoints.
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Figure 30: Percent of RORγt positive cells. Percent of RORγt positive Th17 cells
was not affected by either Rottlerin treatment or Complegen inhibitor treatment.
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Figure 31: MFI of RORγt positive cells. Rottlerin treatment and Complegen
inhibitor treatment, both, increased the median fluorescent intensity of RORγt in
Th17 cells 48 hours after stimulation. No significant differences were observed at
24- and 72-hour time points, following treatement with either inhibitor.

Figure 32: Percent of Nuclear Notch1 positive Th17 cells. Nuclear Notch1 in T
helper 17 cells was slightly decreased by Rottlerin inhibitor while the CGX inhibitor
had no effect.
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Figure 33: MFI of Nuclear and Non-nuclear Notch1 in Th17 cells. The median
fluoresccent intensity of nuclear Notch1 in T helper 17 cells was decreased by
Rottlerin and further decreased by CGX treatement.

Figure 34: Percent of Nuclear pPKCθ (T538) positive Th17 cells. The nuclear
pPKC in T helper 17 cells is slightly decreased by Rottlerin treatment while the CGX
treatment had no effect.
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Figure 35: MFI of Nuclear and Non-nuclear pPKCθ in Th17 cells. The median
fluorescent intensity of nuclear pPKC in T helper 17 cells is decreased by Rottlerin
treatment and further decreased by CGX treatment.
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Figure 36: Percent of pPKCθ (T538) positive Treg cells. Rottlerin treatment
decreased the percent of pPKCθ (T538) positive Tregs, 24 and 48 hours after
stimulation but showed no effect by 72 hours. Complegen inhibitor treatment
decreased the percent of pPKCθ (T538) in Tregs, 72 hours after stimulation, but had
no effect 24 and 48 hours after stimulation.
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Figure 37: MFI of pPKCθ in Treg cells. Rottlerin treatment decreased the median
fluorescent intensity of pPKCθ (T538) in Tregs, 24 and 48 hours after stimulation
but showed no effect at the 72-hour time point. Complegen inhibitor treatment
decreased the median fluorescent intensity of pPKCθ (T538) in Tregs 72 hours after
stimulation but showed no effect at 24- and 48-hour time points.

Figure 38: Percent of Notch1 positive Treg cells. Neither Rottlerin treatment nor
Complegen inhibitor treatment affected the percent of Notch1 positive Treg cells.
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Figure 39: MFI of Notch1 in Treg cells. Rottlerin treatment decreased the median
fluorescent intensity of Notch1 in Treg cells after 24 hours but did not show effects
48 and 72 hours after stimulation. Complegen inhibitor treatment decreased the
median fluorescent intensity of Notch1 by24 hours, with no effect observed at 48and 72-hour timepoints.
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Figure 40: Percent of FOXP3 positive Treg cells. Neither Rottlerin treatment nor
Complegen inhibitor treatment affected the percent of FOXP3 positive Tregs.
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Figure 41: MFI of FOXP3 positive Treg cells. Rottlerin treatment decreased the
median fluorescent intensity of FOXP3 in Tregs by 24 hours after stimulation, but
significantly increased its expression by 72 hours after stimulation. Complegen
inhibitor treatment decreased the median fluorescent intensity of FOXP3 24 and 48
hours after stimulation, but resulted in a slight increase at the 72 hour time point.

Figure 42: Percent of Nuclear Notch1 positive Treg cells. Nuclear Notch1 in
regualtory T cells is decreased by Rottlerin treatment.
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Figure 43: MFI of Nuclear and Non-nuclear Notch1 in Treg cells. The median
fluorescent intensity of nuclear Notch1 in regualtory T cells is decresed by CGX
treatent and further decreased by Rottlerin treatment.

Figure 44: Percent of Nuclear pPKCθ in Treg cells. Nuclear pPKC in regulatory T
cells is slightly decreased by Rottlerin treatment.
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Figure 45: MFI of Nuclear and Non-nuclear pPKCθ in Treg cells. The median
fluorescent intensity of nuclear pPKC in regulatory T cells is decreased by CGX
treatment. Nuclear and non-nuclear pPKC is further decreased by Rottlerin
treatment.

Figure 46: Percent of Nuclear Notch1- and pPKCθ-Colocalizing Treg cells. The
nuclear colocalization of pPKC and Notch1 in regulatory T cells is decreased by
CGX treatment.
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